Neuropharmacology Core

神经药理学核心

基本信息

批准号：
10374825
负责人：
Sidney S Negus
金额：
$ 28.13万
依托单位：
VIRGINIA COMMONWEALTH UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-12-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10374825
关键词：
Acute Address Analgesics Animals Area Behavior Behavioral Behavioral Assay Biological Assay Brain Brain region Cancer Grant Supplements (P30)Chronic Collaborations Collection Consultations Country Data Data Analyses Development Drug abuse Effectiveness Experimental Designs Family Funding Future G-Protein-Coupled Receptors Goals Grant Human Individual Institution Investigational Drugs Laboratories Leadership Measures Mediating Methodology Methods Microdialysis Molecular Molecular Target Neuroanatomy Neuropharmacology Neurotransmitters Nucleus Accumbens Opioid Pain Pathologic Pharmaceutical Preparations Pharmacotherapy Physiological Play Postdoctoral Fellow Procedures Psychological reinforcement Receptor Signaling Recording of previous events Research Research Personnel Research Project Grants Resources Rewards Scientist Self Administration Self Stimulation Serotonin Slice Substance Use Disorder Supervision Synthesis Chemistry System Techniques Tissues Training United States National Institutes of Health Universities Ventral Tegmental Area Virginia abuse liability awake behavioral study conditioned place preference drug action drug of abuse drug reward experience graduate student in vivo innovation meetings monoamine neurochemistry non-drug novel pre-clinical pre-clinical assessment ranpirnase receptor receptor binding receptor expression receptor function reinforcer relating to nervous system substance use treatment tool

项目摘要

Project Summary – Neuropharmacology Core The Neuropharmacology Core is a new core that proposes to serve NIH-funded investigators affiliated with the P30 grant by increasing their access to key neurochemical and behavioral methodologies that are fundamental to advancement of preclinical drug abuse research. These methodologies will include techniques to assess expression and function of receptors in both tissue homogenates and tissue slices, in vivo microdialysis techniques to assess neurotransmitter levels in target brain areas in awake and behaving animals, and behavioral techniques to assess rewarding/reinforcing effects of drugs under different physiological or environmental conditions. Although this is a new core, the investigators have decades of expertise in their respective areas and a history of collaboration both with each other and with other VCU investigators. The rationale for this core is founded on the proposition that drugs of abuse act on molecular targets to modulate activity in brain reward systems and alter behavior, and preclinical drug abuse research benefits from coordinated investigation of drug effects along the entire continuum from molecular to behavioral levels of analysis. However, individual grants typically focus on a portion of this continuum and often lack resources for rapid and rational extension of important findings to other, related research domains. As one example, a synthetic chemistry grant might identify a new molecular entity with promising analgesic effects but lack resources for preclinical assessment of that compound's abuse liability or potential utility as a treatment for substance use disorders. As another example, a grant focused on behavioral studies to treat drug abuse might identify an effective medication strategy but lack resources to investigate candidate mechanisms that underlie medication efficacy. The Neuropharmacology Core proposes to address these gaps and strengthen the breadth and impact of drug abuse research at VCU. Studies of receptor expression and function (Aim 1), in vivo microdialysis (Aim 2), and behavioral expression of reward/reinforcement (Aim 3) will enable investigators to evaluate effects of pathological states or of acute/chronic drug treatments on neural systems and behavioral endpoints known to be important in drug abuse.

项目摘要 - 神经药理学核心神经药理学核心是一个新的核心，该核心提议为NIH资助的研究人员提供服务 P30赠款通过增加其对基本的关键神经化学和行为方法的访问临床前药物滥用研究的进步。这些方法将包括评估的技术受体在组织匀浆和组织切片中的表达和功能，体内微透析评估醒着和行为动物的目标大脑区域中神经递质水平的技术，在不同的生理学或环境条件。尽管这是一个新的核心，但调查人员在其上拥有数十年的专业知识彼此以及其他VCU调查人员的各个领域和合作历史。该核心的理由是建立在以下主张的基础上，即滥用药物对分子靶标的作用调节大脑奖励系统和改变行为的活动，临床前药物滥用研究受益于对整个分子至行为水平的整个药物作用的协调研究分析。但是，个人赠款通常专注于此连续体的一部分，并且通常缺乏资源重要发现的快速，合理地扩展到其他相关的研究领域。作为一个例子，一个合成化学补助金可能会确定一个具有承诺镇痛作用但缺乏承诺的新分子实体用于临床前评估该化合物的滥用责任或潜在效用的资源作为治疗物质使用障碍。作为另一个例子，专注于治疗药物滥用的行为研究的赠款可能确定有效的药物策略，但缺乏资源来调查候选机制的基础用药效率。神经药理学的核心核心提议解决这些差距并加强 VCU吸毒研究的广度和影响。研究受体表达和功能（目标1），体内微透析（AIM 2）和奖励/强化的行为表达（AIM 3）将使研究人员能够评估病理状态或急性/慢性药物治疗对神经元系统和行为的影响终点在药物滥用中很重要。